Novartis agreed to buy Synnovation Therapeutics’ PI3Kα program, paying $2 billion upfront to acquire SNV4818, a mutant‑selective oral inhibitor in early clinical testing. The deal transfers rights to a molecule engineered to spare wild‑type PI3Kα and potentially reduce known class toxicities such as hyperglycemia and rash. Novartis said the acquisition aims to expand options for HR+/HER2‑ breast cancer driven by PIK3CA mutations. SNV4818 is in initial trials across breast and other solid tumors with a primary completion date listed in 2027. Synnovation and Novartis pitched selectivity as the clinical differentiator, positioning the drug for combination regimens and earlier lines of therapy. The move follows similar recent buys in the PI3Kα space and signals continued big‑pharma appetite for next‑generation, mutation‑selective oncology agents.